2017 Q3 Form 10-Q Financial Statement
#000156459017021314 Filed on November 03, 2017
Income Statement
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| Revenue | $42.76M | $21.73M |
| YoY Change | 96.84% | 63.83% |
| Cost Of Revenue | $976.0K | $668.0K |
| YoY Change | 46.11% | 160.94% |
| Gross Profit | $41.79M | $21.06M |
| YoY Change | 98.45% | 61.91% |
| Gross Profit Margin | 97.72% | 96.93% |
| Selling, General & Admin | $16.47M | $10.93M |
| YoY Change | 50.67% | 17.65% |
| % of Gross Profit | 39.41% | 51.91% |
| Research & Development | $11.69M | $7.054M |
| YoY Change | 65.76% | 95.29% |
| % of Gross Profit | 27.98% | 33.5% |
| Depreciation & Amortization | $100.0K | $0.00 |
| YoY Change | ||
| % of Gross Profit | 0.24% | 0.0% |
| Operating Expenses | $11.69M | $17.99M |
| YoY Change | -34.98% | 39.39% |
| Operating Profit | $30.09M | $3.072M |
| YoY Change | 879.62% | 2911.76% |
| Interest Expense | -$40.00K | -$460.0K |
| YoY Change | -91.3% | -34.29% |
| % of Operating Profit | -0.13% | -14.97% |
| Other Income/Expense, Net | $120.0K | -$30.00K |
| YoY Change | -500.0% | |
| Pretax Income | $13.71M | $2.590M |
| YoY Change | 429.34% | -531.67% |
| Income Tax | -$50.00K | |
| % Of Pretax Income | -0.36% | |
| Net Earnings | $13.76M | $2.585M |
| YoY Change | 432.19% | -530.12% |
| Net Earnings / Revenue | 32.17% | 11.9% |
| Basic Earnings Per Share | $0.12 | |
| Diluted Earnings Per Share | $0.11 | $22.25K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 113.6M | 110.7M |
| Diluted Shares Outstanding | 125.7M | 116.4M |
Balance Sheet
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $75.20M | $47.90M |
| YoY Change | 56.99% | 31.23% |
| Cash & Equivalents | $31.06M | $47.87M |
| Short-Term Investments | $44.10M | |
| Other Short-Term Assets | $3.100M | $1.400M |
| YoY Change | 121.43% | 16.67% |
| Inventory | $3.800M | $2.327M |
| Prepaid Expenses | ||
| Receivables | $11.90M | $8.236M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $93.90M | $59.78M |
| YoY Change | 57.07% | 32.26% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $600.0K | $145.0K |
| YoY Change | 313.79% | 45.0% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $1.500M | |
| YoY Change | ||
| Other Assets | $14.70M | $24.00K |
| YoY Change | 61150.0% | -99.23% |
| Total Long-Term Assets | $16.80M | $3.149M |
| YoY Change | 433.5% | -1.59% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $93.90M | $59.78M |
| Total Long-Term Assets | $16.80M | $3.149M |
| Total Assets | $110.7M | $62.93M |
| YoY Change | 75.91% | 30.02% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $6.200M | $4.309M |
| YoY Change | 43.88% | 153.47% |
| Accrued Expenses | $18.10M | $6.874M |
| YoY Change | 163.31% | 102.18% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | $18.73M |
| YoY Change | -100.0% | 38.7% |
| Total Short-Term Liabilities | $24.40M | $31.68M |
| YoY Change | -22.99% | 68.53% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $24.40M | $31.68M |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $24.40M | $31.68M |
| YoY Change | -22.99% | -9.22% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$291.5M | -$326.9M |
| YoY Change | -10.83% | |
| Common Stock | $111.0K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $86.30M | $31.25M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $110.7M | $62.93M |
| YoY Change | 75.87% | 30.02% |
Cashflow Statement
| Concept | 2017 Q3 | 2016 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $13.76M | $2.585M |
| YoY Change | 432.19% | -530.12% |
| Depreciation, Depletion And Amortization | $100.0K | $0.00 |
| YoY Change | ||
| Cash From Operating Activities | $11.00M | $8.900M |
| YoY Change | 23.6% | 888.89% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$100.0K | -$100.0K |
| YoY Change | 0.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$11.50M | |
| YoY Change | ||
| Cash From Investing Activities | -$11.60M | -$100.0K |
| YoY Change | 11500.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -1.800M | -2.800M |
| YoY Change | -35.71% | 86.67% |
| NET CHANGE | ||
| Cash From Operating Activities | 11.00M | 8.900M |
| Cash From Investing Activities | -11.60M | -100.0K |
| Cash From Financing Activities | -1.800M | -2.800M |
| Net Change In Cash | -2.400M | 6.000M |
| YoY Change | -140.0% | -1100.0% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $11.00M | $8.900M |
| Capital Expenditures | -$100.0K | -$100.0K |
| Free Cash Flow | $11.10M | $9.000M |
| YoY Change | 23.33% | 900.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-14000 | |
| CY2017Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-291476000 | |
| CY2017Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
86302000 | |
| CY2017Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
110672000 | |
| CY2017Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
114082000 | |
| CY2017Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
280000000 | |
| CY2017Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
114082000 | |
| CY2017Q3 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
42763000 | |
| CY2016Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
18653000 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9529000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5101000 | ||
| us-gaap |
Accretion Expense
AccretionExpense
|
456000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
14000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
58000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2012000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
344000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
825000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1122000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
12965000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3922000 | ||
| us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
425000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
7299000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
0 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
36052000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
390000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
45618000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-46008000 | ||
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
4614000 | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
15134000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-10520000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-20476000 | ||
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
40435000 | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
679000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
2984000 | ||
| us-gaap |
Accretion Expense
AccretionExpense
|
1562000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
16000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
72000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2015000 | ||
| us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
604000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
3617000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-158000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
13822000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
119000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-119000 | ||
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
4073000 | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
10346000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-6273000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
7430000 | ||
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
47865000 | |
| CY2016Q3 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
5767000 | |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
10175000 | ||
| CY2017Q3 | cort |
Earnings Per Share Potentially Dilutive Securities Stock Options Outstanding
EarningsPerSharePotentiallyDilutiveSecuritiesStockOptionsOutstanding
|
20729000 | |
| us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
639000 | ||
| CY2016Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1831000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9529000 | ||
| CY2017Q3 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
12048000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We reevaluate our estimates and assumptions each quarter, including those related to revenue recognition, sales returns, inventory, allowances for doubtful accounts and accrued liabilities, including our bonus accrual, clinical trial accruals and stock-based compensation<font style="color:#000000;">.</font></p></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">We are subject to credit risk from our portfolio of cash, cash equivalents and marketable securities.  We limit our investments to U.S. Treasury obligations and high-grade corporate debt with less than a 36-month maturity.  We are not exposed to any significant concentration of credit from these investments.<font style="font-size:12pt;"> </font></p></div> | ||
| us-gaap |
Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
|
<div> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Net Product Sales</p> <p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">We primarily sell Korlym directly to patients through a specialty pharmacy. We recognize revenue upon the delivery of Korlym <font style="color:#000000;">if (i) there is persuasive evidence that an arrangement exists with the customer, (ii) collectability is reasonably assured and (iii) the sales price is fixed or determinable. In order to conclude that the price is fixed or determinable, we must be able to (i) calculate gross product revenue from a sale and (ii) reasonably estimate the associated net revenue. </font>Confirmation of coverage by the patient’s private or government insurance plan or by a third-party charity is a prerequisite for selling Korlym to a patient<font style="color:#000000;">. We provide Korlym at no cost to patients without insurance who do not qualify for charitable support. </font></p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through August 9, 2017 our exclusive specialty pharmacy was Dohmen Life Science Services (“Dohmen”). On August 10, 2017, Optime Care, Inc. (“Optime”) became our exclusive specialty pharmacy.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also sell Korlym to a specialty distributor (“SD”), which we recognize at the time the SD receives the Korlym. SD sales were less than two percent of our net revenue in the three and nine months ended September 30, 2017.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We donate cash to charities that help patients with financial need pay for the treatment of Cushing’s syndrome. We do not include payments we receive from these organizations in revenue.</p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate gross product revenues based on the price we charge our customers. We estimate net product revenues by deducting from gross product revenues (a) estimated government rebates, (b) estimated costs of our patient co-pay assistance program, (c) discounts for prompt payment and (d) reserves for expected product returns.  We record estimates for these deductions at the time we recognize the gross revenue and update them as new information becomes available<font style="color:#000000;">.</font></p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rebates and Chargebacks:<font style="font-style:normal;"> </font><font style="color:#000000;font-style:normal;"> Korlym is eligible for purchase by or qualifies for partial or full reimbursement from Medicaid and other government programs. We estimate any government rebate amounts by applying the discount rates applicable to each government-funded program against our sales to patients covered by such programs</font><font style="font-style:normal;">.</font></p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Allowances for Patient Assistance Program:<font style="font-style:normal;">  It is our policy that no patient be denied Korlym due to inability to pay. </font><font style="color:#000000;font-style:normal;">We provide financial assistance to eligible patients whose insurance policies require them to pay high deductibles and co-payments. We determine the amount of such assistance by applying our program guidelines to all eligible sales in the period</font><font style="font-style:normal;">.</font></p> <p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sales Returns<font style="font-style:normal;">: We deduct from each period’s gross revenue the amount of Korlym we estimate will be returned. When estimating returns, we analyze quantitative and qualitative information including, but not limited to, historical return rates, the amount of product in the distribution channel, the expiration date of the product, current and projected product demand, the introduction of competing products that may erode demand, and broad economic and industry-wide indicators. If we cannot reasonably estimate product returns with respect to a particular sale, we defer recognition of revenue from that sale until we can make a reasonable estimate.</font></p></div> | ||
| us-gaap |
Accretion Expense
AccretionExpense
|
15000000 | ||
| CY2017Q3 | cort |
Contractual Obligation Payment To Date
ContractualObligationPaymentToDate
|
45000000 | |
| CY2016Q4 | cort |
Contractual Obligation Payment To Date
ContractualObligationPaymentToDate
|
29866000 | |
| CY2017Q3 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | |
| CY2017Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
0 | |
| CY2016Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
0 | |
| CY2017Q3 | us-gaap |
Contractual Obligation
ContractualObligation
|
45000000 | |
| CY2016Q4 | us-gaap |
Contractual Obligation
ContractualObligation
|
45000000 | |
| CY2017Q3 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
140000 | |
| us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2019-03-31 | ||
| CY2017Q3 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
279000 | |
| CY2016Q3 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
246000 | |
| us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
786000 | ||
| CY2017Q3 | cort |
Contractual Obligation Unamortized Discount Premium Net
ContractualObligationUnamortizedDiscountPremiumNet
|
0 | |
| CY2017Q3 | us-gaap |
Accretion Expense
AccretionExpense
|
37000 | |
| CY2016Q3 | us-gaap |
Accretion Expense
AccretionExpense
|
455000 | |
| dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
1998-05-01 | ||
| dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Delaware | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2017Q3 | cort |
Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
|
1122000 | |
| CY2016Q4 | cort |
Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
|
1848000 | |
| CY2017Q3 | cort |
Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
|
1934000 | |
| CY2016Q4 | cort |
Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
|
1414000 | |
| CY2017Q3 | cort |
Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
|
2452000 | |
| CY2016Q4 | cort |
Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
|
1902000 | |
| CY2017Q3 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
5508000 | |
| CY2016Q4 | cort |
Inventory Current Noncurrent
InventoryCurrentNoncurrent
|
5164000 | |
| CY2017Q3 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
6955000 | |
| CY2016Q4 | cort |
Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
|
3426000 | |
| CY2017Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7886000 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
4702000 | |
| CY2017Q3 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
415000 | |
| CY2016Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
308000 | |
| CY2017Q3 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
342000 | |
| CY2016Q4 | cort |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
164000 | |
| CY2017Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
247000 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
34000 | |
| CY2017Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
407000 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
319000 | |
| CY2016 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
0 | |
| cort |
Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
|
P2Y | ||
| cort |
Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
|
P4M | ||
| CY2017Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2017Q3 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2016Q4 | cort |
Contractual Obligation Unamortized Discount Premium Net
ContractualObligationUnamortizedDiscountPremiumNet
|
456000 | |
| CY2017Q3 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
0 | |
| CY2016Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
14000 | |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
264000 | |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1256000 | |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
314000 | |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
0 | |
| CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
1834000 | |
| us-gaap |
Loss Contingency Accrual Provision
LossContingencyAccrualProvision
|
0 | ||
| cort |
Number Of Stock Option Plans
NumberOfStockOptionPlans
|
2 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
1372000 | ||
| CY2017Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3623000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5101000 | ||
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
5045000 | ||
| CY2016Q3 | cort |
Earnings Per Share Potentially Dilutive Securities Stock Options Outstanding
EarningsPerSharePotentiallyDilutiveSecuritiesStockOptionsOutstanding
|
18570000 | |
| CY2017Q3 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
0 |
